MASON, Ohio– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has launched the EnCompass Clamp®, a part of the Isolator Synergy™ Ablation System in the United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.
The EnCompass Clamp includes features such as parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF). The new features of the EnCompass Clamp allow for easier placement using a magnetic guide, which enables more efficient procedures by minimizing tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are passionate about innovation, leading to high-quality options for our physician partners. We believe the EnCompass Clamp will meet the unique needs of surgeons who are performing closed-atrium cardiac surgery.”
“This new device has become an invaluable part of the way I perform surgical ablation,” said Dr. Prem Samuel, a cardiothoracic surgeon at Midwest Heart & Vascular Specialists, Kansas City, Missouri. “It is used with minimal dissection and creates lesions around the pulmonary veins and the entire posterior wall of the left atrium without opening the atrium, all in a single pass through the transverse and oblique sinuses. I’ve seen firsthand the gains in efficiency that the EnCompass Clamp can bring to my practice and patients.”
